A double blind, randomised, placebo controlled, parallel group study of Sativex when added to the existing treatment regimen, in the relief of post-herpetic neuralgia.

Trial Profile

A double blind, randomised, placebo controlled, parallel group study of Sativex when added to the existing treatment regimen, in the relief of post-herpetic neuralgia.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Postherpetic neuralgia
  • Focus Therapeutic Use
  • Sponsors GW Pharmaceuticals
  • Most Recent Events

    • 28 Jul 2017 Status changed from recruiting to discontinued.
    • 14 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top